{
  "image_filename": "table_p4_det_3_003.png",
  "image_path": "Treanor_et_al.__2011_/extracted/figures/table_p4_det_3_003.png",
  "image_type": "Table",
  "page_number": 4,
  "block_id": "det_3_003",
  "claim_id": "claim_005",
  "claim": "Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
  "supports_claim": false,
  "explanation": "Table showing pre- and post-vaccination geometric mean antibody titers (with 95% CIs) and % response rates for groups: Placebo, FluBlok, FluBlok PV, and FluBlok NPV against three influenza antigens (A/Solomon Island/3/2006 H1N1, A/Wisconsin/67/2005 H3N2, B/Malaysia/2506/2004). does not support the claim because the table does not include any data for Fluarix and only compares FluBlok formulations and placebo. Note: Based solely on the visible table content; no mention of Fluarix was found in the provided excerpt.",
  "model_used": "o4-mini",
  "detailed_analysis": {
    "supports_claim": false,
    "image_description": "Table showing pre- and post-vaccination geometric mean antibody titers (with 95% CIs) and % response rates for groups: Placebo, FluBlok, FluBlok PV, and FluBlok NPV against three influenza antigens (A/Solomon Island/3/2006 H1N1, A/Wisconsin/67/2005 H3N2, B/Malaysia/2506/2004).",
    "evidence_found": null,
    "reasoning": "does not support the claim because the table does not include any data for Fluarix and only compares FluBlok formulations and placebo.",
    "confidence_notes": "Based solely on the visible table content; no mention of Fluarix was found in the provided excerpt."
  }
}